Soleus Capital

Founded 2018
Founders Guy Levy

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 19
Average round size
info
The average size of a deal this fund participated in
$84M
Portfolio companies 23
Rounds per year 6.33
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 10
Key employees Soon
Stages of investment
Early Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Genetics
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Soleus Capital:
Typical Co-investors
Soleus Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Soleus Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States, Greenwich
Funds with similar focus located in United States, Greenwich:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Arcus Ventures United States, New York
Alpha Edison United States, Los Angeles
Currency Capital United States, Los Angeles
Adler Chomsky & Warsawasky Israel, Tel Aviv
Washington Research Foundation. United States, Seattle
Manifold Partners United States, Francisco
P3 Technology Partners -
Topline Capital United States, Villa Park
Yihui Touzi China, Shenzhen
New Age Capital United States, New York
Pathway Capital Management United States, Irvine
Wutong Ideal Capital Management China, Beijing
Drayton Park Capital United States, Radnor
Tianjin Wanrong Wenfu Zichan Guanli Zhongxin (Youxian Hehuo) China, Guangdong
Brill Capital -
Growth Capital Fund by Co-Hub Nigeria, Lagos
Zokyo -
Tracxn Syndicate India, Bangalore

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Artios Pharma

Biopharma
Biotechnology
Medical Device
1
$150M27 Jul 2021 United Kingdom, Cambridge

Notal Vision

Health Care
Medical
Medical Device
1
$60M01 Jun 2021 United States, " United States"}

Genapsys

Biotechnology
Genetics
Health Diagnostics
Information Technology
Medical
1
$70M27 May 2021 United States, Redwood City

TwinStrand Biosciences

Biotechnology
Genetics
Health Care
1
$50M06 May 2021 United States, Seattle

NeoGenomics

Biotechnology
Genetics
Health Care
Health Diagnostics
Medical
Pharmaceutical
n/a
$200M05 May 2021 United States, Fort Myers

Arcellx

Biopharma
Health Care
Pharmaceutical
1
$115M13 Apr 2021 United States, " United States"}

Antios Therapeutics

Biopharma
Biotechnology
Therapeutics
1
$96M12 Apr 2021 United States, Atlanta

Inivata

Biotechnology
Genetics
Health Care
Medical Device
1
$35M04 Feb 2021 United States, Cambridge

IO Biotech

Biotechnology
Health Care
Therapeutics
1
$149M13 Jan 2021 Denmark, Copenhagen
News
Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

DiCE Molecules Announces $60 Million Series C-1 Financing

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Soleus Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: